Pfizer logo

Pfizer Income Statement

Revenue, expenses, and profitability over time

Pfizer generated $63.3B in trailing twelve-month revenue, up 0.0% year-over-year. Net income was $12.1B with a 19.12% net margin. Diluted EPS is $2.12, which grew 0.5% year-over-year. Based on the Q1 2026 filing.

Latest FilingQ1 2026
Report Date2026-05-05
Market Cap$147.62B
P/E Ratio12.19
ROE13.42%

Earnings Per Share

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Basic earnings per share from continuing operations$0.1$0.5$0.5$0.6$0.5
Diluted earnings per share from continuing operations$0.1$0.5$0.5$0.6$0.5
Diluted earnings per share from discontinued operations$0.0$0.0$0.0$0.0$0.0$0.0
EPS from Discontinued Operations, Diluted$0.0$0.0$0.0$0.0$0.0$0.0
Basic EPS from Continuing Operations$0.1$0.5$0.5$0.6$0.5
Diluted EPS from Continuing Operations$0.1$0.5$0.5$0.6$0.5
EPS from Continuing Operations$0.1$0.5$0.5$0.6$0.5
Diluted EPS from Discontinued Operations$0.0$0.0$0.0$0.0$0.0$0.0
Diluted EPS from continuing operations$0.1$0.5$0.5$0.6$0.5
Basic earnings per share$0.07$0.52$0.51$0.62$0.47
Basic EPS from discontinued operations$0.00$0.00$0.00$0.00$0.00$0.00
Diluted earnings per share$0.07$0.52$0.51$0.62$0.47
Continuing operations (in dollars per share)$0.07$0.52$0.51$0.62$0.48
Continuing operations (in dollars per share)$0.07$0.52$0.51$0.62$0.47
Discontinued operations (in dollars per share)$0.00$0.00$0.00$0.00$0.00$0.00
EPS from Continuing Operations$0.1$0.5$0.5$0.6$0.5
Basic EPS from Continuing Operations$0.1$0.5$0.5$0.6$0.5
Diluted EPS from Continuing Operations$0.1$0.5$0.5$0.6$0.5
Diluted EPS from Discontinued Operations$0.0$0.0$0.0$0.0$0.0$0.0
Basic EPS from continuing operations$0.1$0.5$0.5$0.6$0.5
Diluted EPS from continuing operations$0.1$0.5$0.5$0.6$0.5
Diluted EPS from discontinued operations$0.0$0.0$0.0$0.0$0.0$0.0
Diluted EPS from Continuing Operations$0.1$0.5$0.5$0.6$0.5
Diluted EPS from Discontinued Operations$0.0$0.0$0.0$0.0$0.0$0.0
EPS - Discontinued Operations (Diluted)$0.0$0.0$0.0$0.0$0.0$0.0
Diluted EPS from discontinued operations$0.0$0.0$0.0$0.0$0.0$0.0
EPS from continuing operations$0.1$0.5$0.5$0.6$0.5
Discontinued operations per diluted share$0.0$0.0$0.0$0.0$0.0$0.0
Basic EPS from continuing operations$0.1$0.5$0.5$0.6$0.5
EPS from Discontinued Operations (Diluted)$0.0$0.0$0.0$0.0$0.0$0.0
Weighted-average shares, basic1M5.7B5.7B5.7B1M5.7B
Weighted-average shares, diluted1M5.7B5.7B5.7B3M5.7B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Capital Expenditures$917.0M$564.0M$618.0M$602.0M$845.0M$436.0M
Income Taxes Paid, Net$433.0M$152.0M$3.3B$178.0M$1.0B$72.0M
Interest Paid, Net$1.4B$353.0M$1.1B$275.0M$981.0M$293.0M
Deferred taxes-$396.0M-$663.0M-$272.0M-$765.0M-$433.0M-$12.0M
Income Taxes Paid, Net$433.0M$152.0M$3.3B$178.0M$1.0B$72.0M
Interest Paid, Excluding Capitalized Interest, Operating Activity$1.4B$353.0M$1.1B$275.0M$981.0M$293.0M
Interest rate hedges$147.0M$74.0M$66.0M$45.0M$62.0M
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation-$5.1B-$5.2B-$3.2B-$2.5B$0.0-$2.9B
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation$3.3B$4.0B-$2.4B-$6.1B$785.0M
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation$6.7B$2.3B$0.0$4.6B$5.3B$2.6B
Other Noncash Income (Expense)$1.8B-$40.0M$101.0M$292.0M$117.0M$93.0M
Other income, net (Note 6)-$2.4B-$953.0M-$739.0M-$517.0M-$4.5B-$861.0M
Payment for (Proceeds from) Other Investing Activity-$15.0M-$300.0M-$14.0M-$22.0M
Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less-$487.0M$3.9B$583.0M$792.0M
Payments to Acquire Property, Plant, and Equipment$917.0M$564.0M$618.0M$602.0M$845.0M$436.0M
Payments to Acquire Short-Term Investments$6.2B$2.8B$3.3B$4.2B$4.0B$2.6B
Financing — other-$14.0M-$356.0M-$21.0M-$38.0M-$43.0M-$284.0M
Short-term borrowings/(repayments) less than 90 days — net-$386.0M-$517.0M-$127.0M
Proceeds from redemptions/sales of long-term investments$29.0M$82.0M$63.0M$359.0M$591.0M$88.0M
Sales of and distributions from equity method investments$3.5B$6.3B$0.0
Repayments of Short-Term Debt$3.5B$2.0B$151.0M$0.0
Research and development expense$3.0B$2.2B$2.5B$2.5B$3.2B$2.5B
Stock-based compensation$177.0M$170.0M$203.0M$201.0M$225.0M$272.0M
Cash Dividends on Common Stock$2.4B$2.4B$2.4B$2.4B$2.4B$2.4B